Treatment Figure 2. Stag Unknown* or ( –)
EGFR mu the
PS 0-1
Contraindications to platinumb
• gemcitabine + docetaxel • gemcitabine + paclitaxel • gemcitabine + vinorelbine • vinorelbine + paclitaxel
Nonplatinum combination
No contraindications to platinum
gemcitabine, irinotecan, paclitaxel, vinore [for nonsquamous histology] pemetre
(cisplatin or carboplatin) and (doceta Platinum-based Combination
If carboplatin/paclitaxel then add bevacizumab if not contraindicated
a The FDA approval is based on non-randomized Phase 2 data. b
If cisplatin/vinorelbine, then add cetuximab if EGFR + by IHC
Contraindications to platinum-based therapy include: allergy to cisplatin or carboplatin, baseline hearing loss, renal i emesis prophylaxis, or patient refusal of a platinum drug.
Stable disease or response after 4 cycles
Single-agent chemotherapy
Immediate treatment with alternative
OR
Cycle 5-6, then stop therapy, o and continue single-dru
Progressio
Nonsquamous Histology pemetrexed
Unselected Patients docetaxel or erlotinib
If on bevacizumab should continue un progression or una toxicity.
2nd
Line
1st
Line
